tirzepatide weight loss tampa fl Injections & Clinics Near You Tampa Tirzepatide Weight Loss Injections

Editors Solanki P

No account needed to begin

FDA Approves Awiqli (insulin icodec-abae) as the First and Only Once-Weekly Basal Insulin Treatment for Adults with Type 2 Diabetes PLAINSBORO, N.J., March 26, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycemic control (blood sugar) in adults living with type 2 diabetes.1 This new approval offers the only onceweekly basal insulin option, recognizing the importance of personalized care and the need for treatments that fit different patient routines and preferences for adults living with type 2 diabetes.1,2 Awiqli (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA1 Awiqli offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per week1 The Awiqli approval reflects Novo Nordisk's ongoing efforts to advance healthcare innovation and strengthen support for people living with diabetes "Awiqli is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes

The effect on gastric cancer was designated very uncertain, due to imprecision and inconsistency among the studies

Similarly, in our case series, Patient 2 experienced satisfactory weight loss during semaglutide treatment with only mild, transient, GI-related side effects during the initial dose escalation